Effect of HAART on Salivary Composition and Oxidative Profile in HIV-Infected Patients

被引:6
|
作者
Shahar, Eduardo [2 ]
Pollack, Shimon [2 ]
Kedem, Eynat [2 ]
Hassoun, Gammal [2 ]
Nagler, Rafael [1 ,3 ]
机构
[1] Technion Israel Inst Technol, Rappaport Fac Med, Oral Biochem Lab, Haifa, Israel
[2] Rambam Med Ctr, Inst Allergy Clin Immunol & AIDS, Haifa, Israel
[3] Rambam Med Ctr, Dept Maxillofacial Surg, Haifa, Israel
关键词
Saliva; HIV; AIDS; free radicals; oxidative stress; salivary composition;
D O I
10.2174/157016208785861212
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although it has been widely suggested that oxidative stress contributes to the pathogenesis of HIV infection, salivary composition and its oxidative related aspects have never been studied in HIV patients, both HAART-treated and untreated. Human saliva and serum were collected and analyzed for various biochemical, redox related and immunological parameters from 43 consenting HIV-infected patients (20 untreated and 23 treated with HAART) and 20 healthy controls, age and gender matched. Saliva composition of HIV infected patients was completely altered but returned to normal following HAART. HIV patients had significantly-increased levels of oxidative stress damaging markers, compared to healthy controls. Carbonyl levels increased by 110% (p=0.005), and superoxide dismutase enzyme (SOD) and antioxidant capacity (ImAnOx) levels by 45% and 16% (0.035) respectively, but returned to normal levels in treated patients (p=0.005, p=0.03 and 0.02 respectively). Also, the significantly-altered salivary composition (pH and lactate dehydrogenase (LDH) enzyme) and concentration (calcium (Ca), magnesium (Mg), albumin, salivary total protein, secretory IgA) of HIV-infected patients reverted to normal following HAART treatment. Salivary analysis may be used for assessing patient status: treated vs untreated, based on the increase or decrease in the concentration of a given salivary parameter in the HIV-untreated group vs controls, and a return to normal following the HAART treatment. Salivary collection is simple, non-invasive and not associated with risk of infection spread. Antioxidants in HIV patients may be recommended, as well as local oral means aimed at resuming salivary functions compromised in HIV patients.
引用
收藏
页码:447 / 451
页数:5
相关论文
共 50 条
  • [31] Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART
    Tozzi, V
    Balestra, P
    Serraino, D
    Bellagamba, R
    Corpolongo, A
    Piselli, P
    Lorenzini, P
    Visco-Comandini, U
    Vlassi, C
    Quartuccio, ME
    Giulianelli, M
    Noto, P
    Galgani, S
    Ippolito, G
    Antinori, A
    Narciso, P
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (08) : 706 - 713
  • [32] Cardiovascular disease risk factors in HIV-Infected patients in the HAART era
    Galli, M
    Ridolfo, AL
    Gervasoni, C
    HIV-ASSOCIATED CARDIOVASCULAR DISEASE: CLINICAL AND BIOLOGICAL INSIGHTS, 2001, 946 : 200 - 213
  • [33] Therapeutic Drug Monitoring of Indinavir in HIV-Infected Patients Undergoing HAART
    P. Langmann
    M. Zilly
    B. Weißbrich
    S. Desch
    T. Väth
    H. Klinker
    Infection, 2002, 30 : 13 - 16
  • [34] Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART
    Calza, L
    Manfredi, R
    Chiodo, F
    INFECTION, 2002, 30 (01) : 26 - 31
  • [35] Prevalence of cryptococcal subclinical infection in HIV-infected patients initiating HAART
    Rodriguez, V.
    Klajn, D.
    Molina, A. M.
    Cagnoni, A.
    Russo Lacerna, D.
    Bustamante, J. C.
    Zalazar, N.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 235 - 235
  • [36] Nonorgan-specific autoantibodies in HIV-infected patients in the HAART era
    Iordache, Laura
    Bengoufa, Djaouida
    Taulera, Olivier
    Rami, Agathe
    Lascoux-Combe, Caroline
    Day, Nesrine
    Parrinello, Maguy
    Sellier, Pierre-Olivier
    Molina, Jean-Michel
    Mahr, Alfred
    MEDICINE, 2017, 96 (10)
  • [37] Opportunistic events shortly after beginning HAART in HIV-infected patients
    González-Castillo, J
    Blanco, F
    Soriano, V
    Barreiro, P
    Bravo, MC
    Jiménez-Nácher, I
    González-Lahoz, J
    MEDICINA CLINICA, 2001, 117 (03): : 81 - 84
  • [38] Lipodystrophy Syndrome by HAART in HIV-Infected Patients: Manifestation, Mechanisms and Management
    H. H. Hirsch
    M. Battegay
    Infection, 2002, 30 : 293 - 298
  • [39] Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART
    Calza, L
    Manfredi, R
    Chiodo, F
    AIDS, 2003, 17 (06) : 851 - 859
  • [40] Therapeutic drug monitoring of indinavir in HIV-Infected patients undergoing HAART
    Langmann, R
    Zilly, M
    Weissbrich, B
    Desch, S
    Väth, T
    Klinker, H
    INFECTION, 2002, 30 (01) : 13 - 16